**Gαo potentiates estrogen receptor α activity via the ERK signaling pathway**

Melyssa R Bratton1,2, James W Antoon1, Bich N Duong1, Daniel E Frigo5, Syreeta Tilghman1,2, Bridgette M Collins-Burow1, Steven Elliott1, Yan Tang2, Lilia I Melnik2, Ling Lai3, Jawed Alam4, Barbara S Beckman2, Steven M Hill3, Brian G Rowan1, John A McLachlan2 and Matthew E Burow1

1Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, 1430 Tulane Avenue, SL-78, New Orleans, Louisiana 70112, USA

2Pharmacology and 3Structural and Cellular Biology, Tulane University, New Orleans, Louisiana 70112, USA

4Department of Medical Genetics, Alton-Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA

5Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, USA

(Correspondence should be addressed to M E Burow; Email: mburow@tulane.edu)

---

**Abstract**

The estrogen receptor α (ERα) is a transcription factor that mediates the biological effects of 17β-estradiol (E2). ERα transcriptional activity is also regulated by cytoplasmic signaling cascades. Here, several Gα protein subunits were tested for their ability to regulate ERα activity. Reporter assays revealed that overexpression of a constitutively active Gαo protein subunit potentiated ERα activity in the absence and presence of E2. Transient transfection of the human breast cancer cell line MCF-7 showed that Gαo augments the transcription of several ERα-regulated genes. Western blots of HEK293T cells transfected with ER ± Gαo revealed that Gαo stimulated phosphorylation of ERK 1/2 and subsequently increased the phosphorylation of ERα on serine 118. In summary, our results show that Gαo, through activation of the MAPK pathway, plays a role in the regulation of ERα activity.


---

**Introduction**

Various agents regulate estrogen receptor α (ERα) activity in addition to 17β-estradiol (E2), including peptide growth factors (PGFs) such as epidermal growth factor (EGF) and insulin-like growth factor 1 (IGF1; Ignar-Trowbridge et al. 1992, 1993, 1996, Aronica & Katzenellenbogen 1993, Curtis et al. 1996, Kenney & Dickson 1996, Lee et al. 2001, Klotz et al. 2002). PGFs and E2 often operate in concert to potentiate/ elevate ERα activity to a level above that observed with either factor alone (Ignar-Trowbridge et al. 1993, 1996). Mechanistic studies have revealed that cross talk between the PGF and E2 signaling cascades occurs at the level of ERα, in that PGF activation of cytoplasmic signaling cascades such as the phosphatidylinositol 3-kinase (PI3K)–AKT and MAPK signaling cascades (Dufourny et al. 1997, Bartucci et al. 2001, Dunn et al. 2001, Kato 2001, Brazil et al. 2002, Cantley 2002) ultimately leads to activation of ERα (Martin et al. 2000, Campbell et al. 2001). The MAPKs, including ERK1/2, c-jun N-terminal kinase (JNK), and p38 kinase, are a family of related kinases stimulated by numerous extracellular stimuli including mitogens, peptide hormones, cytokines, and cellular stress (Ballif & Blenis 2001).

Activation of the ERα by cytoplasmic signaling cascades is not limited to PGFs. Recent evidence suggests that factors that activate G-protein-coupled receptors (GPCRs) may also regulate ERα function. Dopamine has been shown to activate ERα-mediated transcriptional activity in the absence (Power et al. 1991) or presence (Smith et al. 1993) of E2. Melatonin has been shown to inhibit breast cancer cell proliferation through modulation of ERα function (Ram et al. 1998, 2000b, Rato et al. 1999, Yuan et al. 2002, Girgert et al. 2003, del Rio et al. 2004). Indeed, melatonin may play a role in breast cancer (Sanchez-Barcelo et al. 2003), as high concentrations of melatonin in human breast cancer tissue have been correlated with good prognosis (Maestroni 1999). Also, the growth and proliferation of a number of breast cancers are influenced by β-adrenergic receptors (Cakir et al. 2002), and β-adrenergic stimulation has been shown to elicit classical ‘estrogenic’ responses, such as increases in uterine weight and ER levels (Re et al. 1993, Sukocheva et al. 2003).

Specificity of GPCR signaling is determined by the types of heterotrimeric GTP-binding proteins (G-proteins) that are recruited to, and activated by, an individual receptor (Rockman et al. 2002). The G-proteins consist of α-, β-, and γ-subunits, and they function as second messengers that
initiate signaling cascades responsible for the regulation of numerous cellular events. The $\Gamma_0$ subunit family includes four distinct subgroups, $\Gamma_0$, $\Gamma_{16}$, $\Gamma_{12}$, and $\Gamma_{13}$ (Downes & Gautam 1999, Radhika & Dhanasekaran 2001), and mutations in $\Gamma_0$ subgroups have been linked to human diseases (Lania et al. 2001, Schulte & Fredholm 2003). Classically, $\Gamma_0$ inhibits and $\Gamma_0$ stimulates CAMP production. However, $\Gamma_0$ signaling is not limited to the CAMP pathway, as all four $\Gamma_0$ subgroups have been shown to regulate kinase-mediated signaling events, including the MAPK and PI3K–AKT pathways (Nava et al. 2002, Marinissen et al. 2003, Radeff-Huang et al. 2004). For example, sphingosine kinase type 1 (SPHK1), the enzyme that phosphorylates sphingosine to form sphingosine 1 phosphate, has been shown to regulate breast cancer cell proliferation and tumorigenesis, possibly through SPHK1’s ability to regulate the level of phosphorylated AKT and ERK1/2 (Nava et al. 2002, Sukocheva et al. 2003).

Recent studies have demonstrated pathological $\Gamma_0$ signaling in several disease types, including immune system dysfunction, infectious diseases, endocrine disorders, heart disease, and cancer (Kimple et al. 2011, Vassart & Costaglola 2011, Kaur et al. 2012). In the endocrine system, altered $\Gamma_0$ has been found in a number of disorders, including those involving the thyroid, hypothalamus, pituitary, pancreas, ovaries, prostate, and breast (Livingstone et al. 1998, Lania et al. 2001, D’Souza et al. 2004, Cotta-Grand et al. 2009, Ogawa et al. 2009, Zhao et al. 2010). In cancer, aberrant $\Gamma_0$ signaling has been found in teratocarcinoma, glioblastoma, neuroblastoma, colon, kidney, lung, gastrointestinal stromal-tumors, acute myeloid leukemia, ovarian, pancreas, thyroid, and breast cancers (Hurst & Hooks 2009, Lamba et al. 2009, Kimple et al. 2011). Recent findings have shed light on the role of $\Gamma_0$ signaling in breast carcinoma. Several somatic mutations in $\Gamma_0$ have been identified and characterized in patient breast biopsies (Ram et al. 2000a, Lamba et al. 2009, Kan et al. 2010, Garcia-Marcos et al. 2011). These mutations primarily result in a constitutively active $\Gamma_0$ phenotype in breast tumors, leading to increased $\Gamma_0$ signaling. However, the exact mechanism and consequence of enhanced $\Gamma_0$ signaling in breast cancer remains poorly characterized. A better understanding of the role of $\Gamma_0$ in ER$\alpha$ signaling would increase our understanding of the mechanisms of cancer biology. Given the ability of GPCRs to activate cytoplasmic signaling events that have previously been shown to potentiate ER$\alpha$ transcriptional activity, we hypothesized that G-protein-coupled signaling pathways may target and regulate the transcriptional activity of ER$\alpha$. The recent identification of naturally occurring $\Gamma_0$ mutants led us to use a constitutively active $\Gamma_0$ vector to simulate the effects of the mutations found in clinical breast tumors. Given the relatively novel discovery of these mutations, in vitro and in vivo models of specific $\Gamma_0$ clinical mutations are currently unavailable. We demonstrated potentiation of ER$\alpha$ activity by $\Gamma_0$, which culminated in increased expression of the estrogen target genes SDF1 (CXCL12), progesterone receptor (PR (PGR)), and BCL2. Mechanistic studies on $\Gamma_0$, revealed that this subunit activated the ERK1/2 signaling pathway, culminating in the phosphorylation of ER$\alpha$.

There is emerging evidence linking the ER to nonclassical, rapid signaling events originating at the cell membrane followed by activation of downstream kinase cascades within the cytoplasm. This study focuses on the ability of the G-protein $\Gamma_0$ to modulate the activity of the ER and explores the cellular pathways through which this regulation takes place.

Materials and Methods

Reagents

DMEM, phenol red-free DMEM, fetal bovine serum (FBS), BME amino acids, MEM amino acids, L-glutamine, penicillin, streptomycin, and sodium pyruvate were obtained from GibcoBRL. Porcine insulin was purchased from Sigma, and charcoal-stripped (CS) FBS was obtained from HyClone (Logan, UT, USA). Effectene was purchased from Qiagen. E$_2$ was obtained from Sigma. BrightGlo luciferase assay substrate was purchased from Promega. The lysis buffer used was mammalian protein extraction reagent (M-PER) from Pierce (Rockford, IL, USA). The Berthold AutoLumat Plus luminometer was used for luciferase assays.

Plasmids

Expression constructs for constitutively active $\Gamma_0$ subunits (GTPase-deficient mutants of $\Gamma_0$, $\Gamma_{12}$, $\Gamma_{13}$, $\Gamma_{16}$) were generously provided by Dr Lynn Heasley (Heasley et al. 1996) or obtained through the UMR cDNA Resource Center (Rolla, MO, USA). We have previously described the use of dominant-negative mutant ERK2-DN, which was provided by Drs Melanie Cobb and Roger Davis (Frigo et al. 2004). The pCDNA3.1-ER$\alpha$ plasmids along with pERE-Luc plasmid, which contains three copies of the estrogen response element (ERE) linked to the luciferase gene, were purchased from Panomics (Fremont, CA, USA). ER$\alpha$-S118A was provided by Benita Katzenellenbogen (Le Goff et al. 1994).

Cell culture

The two cell lines used were the ER-negative human embryonic kidney 293 (HEK293; Le Goff et al. 1994), and the ER$\alpha$- and ER$\beta$-positive human breast carcinoma (MCF-7) cell lines (Frigo et al. 2002). All were maintained in DMEM supplemented with 10% FBS, BME amino acids, MEM amino acids, L-glutamine, 100 units/ml penicillin, 100 units/ml streptomycin, sodium pyruvate, and 1X 10$^{-10}$ M porcine insulin under mycoplasma-free conditions at 37 °C in humidified 5% CO$_2$. For described studies, cells were grown in phenol red-free DMEM supplemented with
5% CS FBS, and supplements as earlier, but without insulin (5% CS-DMEM) as described previously (Igmar-Trowbridge et al. 1993, Burow et al. 1999).

**Transient transfection and luciferase assay**

HEK293T and MCF-7 cells were transfected as described previously (Burow et al. 1999). Briefly, cells were plated into 24-well plates at 1 X 10⁴ cells/well in 5% CS-DMEM and allowed to attach overnight. The next day, the cells were transfected with plasmids for 5 h in the serum/supplement-free DMEM using Effectene according to the manufacturers’ protocols. The following amounts of DNA were added to each well: for ERE-luc assays, 0-2 μg ERE-luciferase, 0-3 μg G-proteins, 0-2 μg ER (S118A), and 0-1 μg ERE-luc. After 5 h, the cells were treated with vehicle control or E2 (10 pM). After 24 h, the treatment-containing medium was removed and 1 X M-PER mammalian cell lysis buffer (Pierce; 150 μl) was added per well and gently shaken for 5 min at room temperature. Luciferase activity of 100 μl of cell extract was determined using BrightGlo luciferase assay substrate (Promega) in a Berthold luminometer. Data are presented as relative luminescence and are normalized as outlined in each figure. Each data point is the average of three separate measurements. Statistical analysis was performed using the two-sample T test in the Origin graphing program with a P value of 0.05.

**Western blot analysis**

HEK293 cells were maintained in 5% CS-DMEM and placed in 100 × 20 mm cell culture dishes at 50–80% confluency overnight. Cells were transfected with 1 μg ERα and either 1 μg empty vector or 1 μg Gaα. For RT-PCR analyses, MCF-7 cells were transfected with either empty vector or 2-0 μg Gaα. After 5 h, either steroid or vehicle was added. The cells were harvested after ~18 h using M-PER lysis buffer containing a mixture of protease inhibitors (Roche) and phosphatase inhibitors (Sigma) on ice for 10 min. Equal volumes of lysates were added to SDS–PAGE loading buffer (Invitrogen) containing 1% β-mercaptoethanol and then boiled for 5 min. The proteins were electrophoresed on a Bis–Tris 4–12% gradient polyacrylamide gel (Invitrogen) and were subsequently transferred electrophoretically to a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk solution in PBS and 0-1% Tween for 1 h at room temperature. The membrane was washed extensively and subsequently incubated overnight at 4°C with rabbit antibodies to ERα (1:500 dilution; Santa Cruz Biotechnology); ERα-phospho-S118 (1:1000 dilution; Cell Signaling, Beverly, MA, USA); phosphorylated forms of ERK1/2, JNK, or p38 (1:1000; Cell Signaling Technology); or Rho-GDI (1:500 dilution; Santa Cruz Biotechnology). All antibodies were diluted in 5% BSA dissolved in 1× PBS+ 0-1% Tween. The next day, blots were washed in PBS+ 0-1% Tween and incubated with goat antirabbit antibodies conjugated to IRDye (1:10 000; Li-Cor, Lincoln, NE, USA) for 60 min at room temperature. Following three washes, immunoreactive proteins were scanned using the Li-Cor IR scanner set to 800 nm.

**RT-PCR assays**

Cell lysates were obtained as explained earlier. RNA was isolated using the RNAeasy miniprep kit (Qiagen). Second-strand cDNA synthesis was performed using 2 μg total RNA and the cDNA synthesis kit (Bio-Rad) according to the manufacturer’s instructions. RT-PCR assays were assembled in 96-well plates using 5 μl of 1:10 dilution of the synthesized cDNA, 0-1 μg of 1:1 mixture of forward and reverse primers, and 1X SYBR-Green solution (Bio-Rad).

**Results**

*G*-proteins potentiate ERα activity

Activation of G-protein signaling can occur in response to classic GPCRs, growth factor/cytokine receptors, and steroid hormones (Rockman et al. 2002, Radeff-Huang et al. 2004). There are four major families of Ga signaling proteins: Gaα1, Gaα, Gaαq, and Gaα12/13. Therefore, we chose the primary members of these four major families to screen for effects on ERα transcriptional activity. To examine the role of specific

![Figure 1](image-url)

*Figure 1* G-proteins enhance estrogen receptor activity. MCF-7 breast carcinoma cells were transfected with ERE-luciferase reporter plasmid (200 ng) along with 300 ng of empty vector (VEC), or constitutively active mutants of Gaα2, Gaα, Gaαq, Gaα12, Gaα13, or Gaα16. Cells were subsequently treated with vehicle control (white bars) or 1 nM E2 (black bars) and were harvested 24 h later for luciferase assay. Data are represented as fold induction (±S.E.M.) with vehicle treatment of VEC cells set to 1-0. Each bar is an average of three experiments. *A statistical significance between the vector vehicle control and each G-protein vehicle control; *a statistically significant difference between the vehicle control and E2 within each G-protein sample (P<0.05).

www.endocrinology-journals.org
Gα subunits on ERα activity, expression vectors containing Gα subunits mutated to function in a constitutively active manner were used. MCF-7 breast carcinoma cells, which contain both the isoforms of ER, were transfected with empty vector (VEC), Gαs-2, Gαq-12, Gαq-13, Gα12, and Gα13, along with an estrogen-responsive luciferase reporter construct. The ability of 1 nM E2 to activate the ER in VEC cells was normalized to 1.0. The expression of Gαs-2, Gαq-12, and Gα13 potentiated estrogen-bound ERα activity (Fig. 1). Interestingly, only Gαs overexpression resulted in both a ligand-independent and a ligand-dependent increase in ERα activity.

Gαs potentiates ER-mediated gene transcription

We focused the remaining studies on Gαs because of its ability to augment ER activity, both in the presence and absence of estrogen. To determine whether Gαs overexpression affects transcription of endogenously ER-regulated genes, we transfected MCF-7 cells with either VEC or constitutively active Gαs, in the absence or presence of 1 nM E2 followed by real-time PCR. In the vector cells, the addition of 1 nM E2 caused an expected increase in the transcription of ERα-regulated genes pS2 (TFF1; fourfold), SDF1 (fivefold), PR (33-fold), and BCL2 (1.8-fold) (Fig. 2A). Transfection of Gαs resulted in an increase in the transcription of PR (2.7-fold), SDF1 (1.9-fold), and BCL2 (twofold) in the absence of estrogen; however, no change was seen in the expression of pS2 after overexpression of Gαs (Fig. 2A). We believe that the latter effect is due, in part, to altered promoter contexts of each ER-mediated gene. Curiously, the addition of Gαs did not increase the transcription of PR, pS2, or SDF1 beyond the level induced by estrogen. It is possible that, with these particular genes, treatment with E2 resulted in a maximum transcriptional response in this cell context. It is important to note that in the cases of PR and SDF1, Gαs alone was able to induce transcription, although to a lesser level than that seen with E2. Finally, we found that the Gαs-mediated increase in expression of these ER-regulated genes was not due to an increase in ERα transcription levels in cells that were transfected with Gαs (Fig. 2B).

Gαs activates the ERK pathway

Several cell signaling cascades have been shown to cross talk with ERα (Dufourny et al. 1997, Martin et al. 2000, Bartucci et al. 2001, Campbell et al. 2001, Dunn et al. 2001, Kato 2001, Brazil et al. 2002, Cantley 2002). To determine whether Gαs activates ERK1/2, p38, or JNK kinases, western blot analysis was performed using phosphorylation-specific antibodies to detect the active forms of these kinases. Transfection of HEK293T cells with constitutively active Gαs resulted in an increase in the phosphorylation of ERK1/2 but not JNK or p38 (Fig. 3). Similar results were seen in MCF-7 cells (data not shown).

Figure 2

Gαs enhances ER-mediated gene expression. Real-time PCR was performed as described in the Materials and Methods section. (A) MCF-7 cells were transfected with either empty vector (vehicle or E2) or constitutively active Gαs. For each gene analyzed, the vehicle control was set to 1.0. (B) MCF-7 cells were transfected as in (A) with either empty vector (Vec) or constitutive active Gap (Gao). ER transcript levels were set to 1.0 in vector samples for comparison. Each experimental condition is an average of three separate samples. *A statistically significant difference (P<0.05).

Gαs affects ERα’s phosphorylation status

Our results indicate that Gαs activates the ERK1/2 pathway. Because ERα contains an ERK phosphorylation site at serine 118, we tested the ability of Gαs overexpression to increase phosphorylation of the ER at this site. We used western blot analysis of HEK293T cells that were transfected with ERα, with or without Gαs. Using densitometry, we divided the overall increase in ER phosphorylation at serine 118 by the total amount of ER within the cell. Our results indicate that Gαs caused an increase in ERα phosphorylation at Ser118 of approximately twofold (Fig. 4A and B).

We validated these findings using a serine 118 to alanine point mutant of ERα in ERE reporter assays. Transfection of the mutant into HEK293T cells showed that alteration of this
residue resulted in loss of the Gαo effect on ERα activity (Fig. 5A). We also used a dominant-negative mutant of ERK2 and found that this mutant was able to decrease Gαo’s potentiation of ligand-bound ERα by ~30% (Fig. 5B). Finally, we showed that when ERK was pharmacologically inhibited by UO126, Gαo’s potentiation of ligand-bound ERα activity fell by ~30% while the inhibitor had no effect on E2-stimulated ERα activity (Fig. 5C). These results confirm that an intact ERK1/2 pathway is necessary for the maximal Gαo effect on ER activity.

Discussion

Rapid, ‘nongenomic’ signaling of estrogen has been the focus of intense research in recent years. E2 has been shown to rapidly (seconds to minutes) activate many signaling molecules (Cheskis 2004, Shupnik 2004, Levin 2005), such as i) IGF1 receptor and EGF receptor, ii) p21ras and Raf, iii) MAPK and Akt, iv) protein kinase C, v) intracellular calcium transients, vi) nitric oxide and prolactin secretion, and vii) Maxi-K channels. However, the mechanisms of these activations remain unclear. Although several groups have proposed that alternative E2-binding proteins exist within the plasma membrane, accumulating evidence supports the classical full-length ERα as the membrane E2-binding protein. Current studies are underway to determine what accessory proteins are associated with and transmit the signal of ERα at the membrane to intracellular signaling cascades and ultimately to the nucleus.

Several laboratories have evidence suggesting that G-proteins provide this link between the ER at the plasma membrane and estrogen-induced rapid kinase activation within the cell. Wyckoff et al. (2001) showed that endothelial nitric oxide synthase (eNOS) stimulation was mediated by plasma membrane-tethered E2-bound ERα and that this stimulation was dependent on ER coupling with Gαi. Razandi et al. (2003) demonstrated that ER interaction with Gαi controls rapid signaling through Src–ERK. In addition, ER has been shown to interact with Gα13, and this interaction stimulates the small GTPase RhoA and the downstream effector Rho-associated kinase (Simoncini et al. 2006).

Here, we investigated the role of the G-protein subunit Gαo, as a mediator of ERα transcriptional activity. We have
shown using ERE-luciferase assays that a constitutively active Gaα is able to potentiate ERα activity in the absence and presence of E2 (Fig. 1). Using RT-PCR analysis of MCF-7 cells transfected with the constitutively active Gaα, we showed a Gaα-mediated potentiation of transcription of the ERα-regulated genes BCL2, SDF1, and PR (Fig. 2). The increase in transcription of these genes was not the result of a Gaα-mediated increase in ERα transcription.

Because several laboratories have previously shown that G-proteins mediate phosphorylation of cellular signaling kinases and that these phosphorylation events can impact ERα activity, we used western blot analysis of HEK293T cells transfected with either pCDNA or constitutively active Gaα to probe the phosphorylation status of several major signaling kinases. We showed that overexpression of Gaα resulted in increased phosphorylation and hence activation of ERK1/2 kinase but not p38 kinase or JNK kinase (Fig. 3). This result led us to explore the phosphorylation status of the ER in the presence and absence of constitutively active Gaα. Again, we used western blot analysis of HEK293T cells that were transfected with ERα±Gaα. Our results indicated an increase in phosphorylation of ERα at serine 118, a known ERK1/2 site (Fig. 4A). Our densitometric analysis showed that serine 118 was in fact hyperphosphorylated as a result of Gaα overexpression (Fig. 4B). In addition, ERE-luciferase assays using an ERK-DN construct, a specific ERK pharmacological inhibitor, or a serine 118 to alanine point mutant of ERα, we confirmed that serine 118 is necessary for a maximal Gaα effect (Fig. 5A, B and C). Previous laboratories have shown a direct link between ERα phosphorylation at serine 118 and an increased ability of the receptor to dimerize and bind coactivators (Sheeler et al. 2003). Therefore, the increased activity of ERα in the presence of Gaα can be partially explained by our evidence linking Gaα to activation of ERK1/2, followed by hyperphosphorylation of ERα at serine 118, and an increase in ER dimerization and coactivator recruitment.

Figure 5  Serine 118 of ERα is necessary for a maximal Gaα effect.
(A) HEK293T cells were transfected with either wild-type ERα or ER (S118A) and either pCDNA or Gaα along with an ERE-luciferase reporter plasmid. Cells were incubated with vehicle control or 10 pM E2. Luminescence values are expressed as relative % change with ER or ER (S118A)±E2 set to 100%. Each condition was performed in triplicate. *A statistical difference between ER and ER (S118A) or E2 set to 100%. (B) MCF-7 cells were transfected with ERE-luciferase reporter plasmid along with empty vector (vec) or constitutively active Gaα and empty vector (vec) or dominant-negative ERK (ERK-DN). Cells were treated with vehicle control (veh) or 1 nM E2. Data are represented as percent estrogen activity (± S.E.M.) relative to E2 treatment (100%). *A significant decrease in Gaα-stimulated estrogen-bound ER activity as a result of ERK-DN (P<0.05). (C) MCF-7 cells were transfected with either vector or Gaα, and were treated with vehicle, E2, U0126 (ERK1/2 inhibitor), or E2+U0126. *A significant decrease in Gaα-stimulated estrogen-bound ER activity as a result of U0126. All experiments were performed in triplicate.
Given that there are multiple physiological mutations resulting in increased G\(a_o\) activity, we chose to use a constitutively active G\(a_o\) variant to mimic increased G\(a_o\) activity in our cell systems. The G\(a_o\) mutant used in our study is GTPase deficient, resulting in a constitutively active G\(a_o\) phenotype, similar to those found in human tumors. There are several known downstream effectors of G\(a_o\), including protein kinase C, Src, Stat3, and c-mos. G\(a_o\) uses these various effectors based on initiating signaling event and tissue type (Kroll et al. 1991, Diverse-Pierluissi et al. 1997, Ram et al. 2000a). While G\(a_o\) has been shown to use MAPKs to exert its effects, the role of MAPKs in G\(a_o\), signaling is less clear. There are varying reports in the literature regarding G\(a_o\) activation of MAPKs. For example, some studies have reported that G\(a_o\) can activate p38 and Erk1/2 signaling while others have shown that G\(a_o\) inhibits Erk1/2 activation (Yamauchi et al. 1997, Liu et al. 2002). Conversely, several studies have demonstrated a relationship between G\(a_o\) and JNK and Akt activity (Goel et al. 2004, He et al. 2006). To date, the majority of these studies have excluded breast tissue in their analysis and ability of G\(a_o\) to regulate MAPK activity in ER-positive cells has not been well characterized.

The vast majority of breast cancers are ER\(\alpha\) positive, and pathological ER\(\alpha\) signaling is the primary growth cascade in these cancers. Therefore, we chose to investigate the relationship between G\(a_o\) and ER pathways. Our findings demonstrate that G\(a_o\) can alter ER\(\alpha\) signaling. Furthermore, we report a relationship between MAPK signaling and G\(a_o\). MAPKs are known to promote hormone-independent tumor growth and endocrine therapy resistance (Musgrove & Sutherland 2009). Furthermore, ligand-independent tumor growth is a hallmark of breast cancer progression (Musgrove & Sutherland 2009). Several mechanisms of ligand-independent activation of the ER have been identified, including increased endogenous activation of the ER through MAPK-specific phosphorylation (Kato et al. 1995). In breast cancer, ERK1/2 is known to activate the ER at the S118 phosphorylation site, which results in enhanced proliferation and tumorigenesis (Kato et al. 1995, Chen et al. 2000). Furthermore, phosphorylation of the ER by ERK1/2 promotes hormone-independent tumor growth and endocrine therapy resistance (Campbell et al. 2001). In the clinic, increased S118 phosphorylation is associated with decreased survival and the efficacy of therapeutic agents may be correlated with activation at this site (Yamashita et al. 2008, Zoubir et al. 2008). Our findings that G\(a_o\) activates ERK1/2, but not p38 or JNK, are similar to previously published studies in prostate but contrast those found in pituitary, kidney, and neuronal cells (Yamauchi et al. 1997, Liu et al. 2002, 2011, He et al. 2006). The fact that mutation of S118 to alanine blocks the G\(a_o\) effect entirely while pharmacological or molecular inhibition of ERK1/2 only partially does so implies that G\(a_o\) may influence other kinases within the cell that ultimately affect phosphorylation of ER at serine 118. These results provide evidence for a tissue-type-specific role of G\(a_o\) activation of MAPK in ER-positive cells.

Identification of G\(a_o\)-induced ER activity mediated by ERK1/2 could provide a novel target for ligand-independent tumors, as well as endocrine therapy-resistant breast cancer. Although further study is needed to determine the therapeutic potential of this pathway, identification and characterization of secondary ER growth pathways are necessary for the development of novel anticancer agents. Our findings that G\(a_o\) promotes ER signaling through the ERK signaling cascade may account for the previously published findings of increased tumorigenesis and tumor growth associated with G\(a_o\) (Nguyen et al. 2002, Prevost et al. 2006, Garcia-Marcos et al. 2011, Lin et al. 2011). Increased understanding of the interplay between G\(a_o\) and the ER may also identify novel breast cancer treatments that target ER signaling. For example, one recent study used a G\(a_o\) inhibitor as an anticancer agent across several cancer types, including ER\(-\)positive breast cancer (Prevost et al. 2006). Given the high rate of endocrine therapy resistance, anticancer therapies directed against G\(a_o\) and indirectly targeting the ER, may be an effective therapeutic strategy. In conclusion, we have shown that G\(a_o\) plays a significant role in the regulation of ER\(\alpha\) activity, both in the presence and absence of E2. Specifically, G\(a_o\) can enhance ERK1/2 phosphorylation. This activation leads to specific phosphorylation of the ER at serine 118, culminating in a marked increase in ER\(-\)mediated transcriptional activity. Our results also indicated that G\(a_o\) can induce ER phosphorylation in the absence of E2, which is especially relevant considering the clinical phenomenon of estrogen-independent proliferation of breast cancer cells. It is important to note that because of the constitutively active nature of the G\(a_o\) construct, we are circumventing the involvement of the GPCR, which is endogenously associated with G\(a_o\). Further studies using wild-type G\(a_o\) overexpression will explore the role, if any, of a GPCR in the G\(a_o\)-ER mechanism. In any case, our results showing a direct link between an activated G-protein- and estrogen-independent phosphorylation and activation of the ER could open a new avenue of research regarding treatment of estrogen-independent and/or tamoxifen-resistant breast cancer.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by National Institutes of Health Grant DK 059389 (to M E B), Department of Energy Grant DE-FC26-00NT40843 (to J A M and M E B), Center for Disease Control Grant RO6/CCR419466-02 (to J A M), the Center for Bioenvironmental Research at Tulane and Xavier Universities (to J A M), the Office of Naval Research Grant N00014-99-1-0763 (J A M and M E B), the Louisiana Cancer Research Consortium (M R B), and the Susan G Komen Breast Cancer Foundation Grant BCTR0601198 (M E B) and National Institutes of Health grant K01 DK084205 (DEF).
Acknowledgements

The authors would like to thank Drs Roger Davis, Pierre Chambon, Donald P McDonnell, Jan-Ake Gustafsson, Benita Katzenellenbogen, Melanie Cobb, and Diane M Klotz for the generous provision of expression constructs and cell lines.

References

Aronica SM & Katzenellenbogen BS 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7 743–752. (doi:10.1210/me.7.6.743)


Received in final form 2 May 2012
Accepted 4 May 2012
Made available online as an Accepted Preprint 4 May 2012